The US held about a third of the global cleanroom market in 2025, according to Mordor Intelligence. These statistics vary by the exact market (build, consumables etc), but is overall a significant portion of all.
There were some significant moves by US-based cleanroom build firms this year, and some market consolidation. US-based AdvanceTEC, a major player in cleanroom design and build, with over 100 employees and $30m in turnover in 2025, was acquired by Equans late in the year. The multibillion-dollar parent company is keen to capitalise on AdvanceTEC’s modular and prefabrication expertise, seeing that as key to its future plans.
Modularity and prefabrication are also key trends in the US, emphasised by many recent launches of modular components from Jansen Cleanroom & Labs and GCS, as well as improvements to full modular solutions from companies like Terra Universal and AES Clean Technology.
In terms of new players, SRBA also entered the US market in late 2024 through a majority stake in Corporate Construction Inc. Corporate Construction’s portfolio includes clients in high-tech and life sciences sectors, spanning nationally across the US. The new “Corporate Construction SRBA” will continue these operations.
UK-based filter expert Cleanova has also made attempts to push into the US market with the acquisition of two US-based HEPA filter companies. The addition of Airflotek and TES-Clean Air Systems to the company portfolio is intended to help the company gain entry into the market for ultra-clean, controlled environments for AI-driven semiconductor manufacturing in the US.
Urgent domestic manufacturing push
The US being such an influential player on the world stage means any small variation in output or policy can have huge knock-on impacts across the entire landscape. There were a number of such events in the last few years.
At the top of a lot of companies’ minds will be the ongoing tariff fluctuations. At the end of 2025, 100% tariffs were instituted on branded or patented pharmaceuticals. However, companies that have broken ground on a facility or have one under construction were exempt. Companies have been talking to the US government on this topic. AstraZeneca reached an agreement with to delay tariffs for 3 years to give them time to realise a $50bn investment in manufacturing in the country.
These urgent reshoring tactics will necessitate a vast amount of cleanroom resources quickly in the country. Many are now questioning whether the workforce currently available will be enough to meet this need, construction and operation-wise.
Cleanroom build resources are not just being demanded from the pharmaceutical sector. With the CHIPS Act still in effect, and eighteen new fabs breaking ground in the US. This piece of legislation created $52bn in incentives for companies to build their semiconductor manufacturing operations in the country. These facilities require ISO Class 4 cleanroom space. Mordor Intelligence states that between all the announcements from manufacturers, this accounts for about 3 million sqft.
Between pharma and hi-tech production, there is going to be a huge demand for cleanrooms in the near future, and supply will need to rise to meet demand. Companies like US-based Angstrom Technology have even launched a life science-specific business segment to address the potential shortage in expertise.
Urgent reshoring tactics will necessitate a vast amount of cleanroom resources quickly in the country
Regulation changes catalysing change
Outside of business moves, regulation changes are also impacting companies using cleanrooms. This includes the introduction of the new